High Dose Tamoxifen For Brain Tumors
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

Tamoxifen Reference List
Click HERE to go back to the Tamoxifen Paper

1.   Al-Nabulsi, I., R.H. Mach, L.M. Wang, C.A. Wallen, P.C. Keng, K. Sten, Childers, SR, and K.T. Wheeler.
  Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. British Journal of Cancer 81: 925-933, 1999.
2.   Allen, M.C., C. Newland, M.A. Valverde, and S.P. Hardy.
  Inhibition of ligand-gated cation-selective channels by tamoxifen. European Journal of Pharmacology 354: 261-269, 1998.
3.   Anonymous.
  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet351: 1451-1467, 1998.
4.   Assikis, V.J., P. Neven, V.C. Jordan, and I. Vergote.
  A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. [Review] [75 refs]. European Journal of Cancer 32A: 1464-1476, 1996.
5.   Baltuch, G.H., N.P. Dooley, J.G. Villemure, and V.W. Yong.
  Protein kinase C and growth regulation of malignant gliomas. [Review] [98 refs]. Canadian Journal of Neurological Sciences 22: 264-271, 1995.
6.   Baltuch, G.H., N.P. Dooley, K.M. Rostworowski, J.G. Villemure, and V.W. Yong.
  Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. Journal of Neuro-Oncology 24: 241-250, 1995.
7.   Baltuch, G.H. and V.W. Yong.
  Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. Brain Research 710: 143-149, 1996.
8.   Bedford, G.R. and D.N. Richardson.
  Preparation and identification of cis and trans isomers of a substituted triarylethylene. Nature 212: 7331966.
9.   Ben, A.M., S. Postovsky, D. Goldsher, H.R. el, and S. Constantini.
  . Clinical and radiographic response in three children with recurrent malignant cerebral tumors with high-dose tamoxifen. Pediatric Hematology & Oncology 16: 245-250, 1999.
10.   Bergan, R.C., E. Reed, C.E. Myers, D. Headlee, O. Brawley, H.K. Cho, W.D. Figg, A. Tompkins, W.M. Linehan, D. Kohler, S.M. Steinberg, and M.V. Blagosklonny.
  . A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clinical Cancer Research 5: 2366-2373, 1999.
11.   Brandes, A.A., M. Ermani, S. Turazzi, E. Scelzi, F. Berti, P. Amista, Rotilio, C. Licata, and M.V. Fiorentino.
  Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. Journal of Clinical Oncology 17: 645-650, 1999.
12.   Bredel, M. and I.F. Pollack.
  The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. [Review] [188 refs]. Acta Neurochirurgica 139: 1000-1013, 1997.
13.   Broniscer, A., C.C. Leite, V.L. Lanchote, T.M. Machado, and L.M. Cristofani.
  . Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. Journal of Clinical Oncology 18: 1246-1253, 2000.
14.   Carlson, R.W.
  . Scientific review of tamoxifen. Overview from a medical oncologist. [Review] [19 refs]. Seminars in Oncology 24: S1-S11997.
15.   Chamberlain, M.C. and P.A. Kormanik.
  Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Archives of Neurology 56: 703-708, 1999.
16.   Chang, J.C.
  A review of breast cancer chemoprevention. [Review] [19 refs]. Biomedicine & Pharmacotherapy 52: 133-136, 1998.
17.   Chang, S.M., F.G. Barker, S.L. Huhn, M.K. Nicholas, M. Page, J. Rabbitt, and M.D. Prados.
  High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. Journal of Neuro-Oncology 37: 169-176, 1998.
18.   Cho, K.K., T. Mikkelsen, Y.J. Lee, F. Jiang, M. Chopp, and M.L. Rosenblum.
  The role of protein kinase C alpha in U-87 glioma invasion. International Journal of Developmental Neuroscience 17: 447-461, 1999.
19.   Cloughesy, T.F., R.P. Woods, K.L. Black, W.T. Couldwell, R.E. Law, and D.R. Hinton.
  Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. Journal of Neuro-Oncology 35: 39-45, 1997.
20.   Cokgor, I., H.S. Friedman, and A.H. Friedman.
  Chemotherapy for adults with malignant glioma. [Review] [92 refs]. Cancer Investigation 17: 264-272, 1999.
21.   Couldwell, W.T., M.H. Weiss, C.M. DeGiorgio, L.P. Weiner, D.R. Hinton, Ehresmann, GR, P.S. Conti, and M.L. Apuzzo.
  . Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-489, 1993.
22.   Couldwell, W.T., M.H. Weiss, R.E. Law, and D.R. Hinton.
  Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas. Journal of Neurosurgery 82: 461-468, 1995.
23.   Couldwell, W.T., D.R. Hinton, A.A. Surnock, C.M. DeGiorgio, L.P. Weiner , M.L. Apuzzo, L. Masri, R.E. Law, and M.H. Weiss.
  . Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clinical Cancer Research 2: 619-622, 1996.
24.   Damek, D.M. and F.H. Hochberg.
  Clinical aspects of brain tumor. [Review] [49 refs]. Current Opinion in Neurology 10: 452-458, 1997.
25.   daMotta LA and daMotta LD.
  . [Endocrine treatment of meningiomas: a review]. [Review] [45 refs] [Portuguese]. Arquivos de Neuro-Psiquiatria 53: 324-332, 1995.
26.   daRocha AB, D.R. Mans, E.A. Bernard, C. Ruschel, A.F. Logullo, L.A. Wetmore, A. Leyva, and G. Schwartsmann.
  Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. European Journal of Cancer 35: 833-839, 1999.
27.   DeMattia, J.A., W. Zhang, and W.T. Couldwell.
  . Tyrosine kinase inhibitors - potential for the treatment of primary brain tumours. CNS DRUGS 12: 421-430, 1999.
28.   Donson, A.M., M.D. Weil, and N.K. Foreman.
  Tamoxifen radiosensitization in human glioblastoma cell lines. Journal of Neurosurgery 90: 533-536, 1999.
29.   Ducharme, J., K. Fried, G. Shenouda, B. Leyland-Jones, and I.W. Wainer.
  Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. British Journal of Clinical Pharmacology 43: 189-193, 1997.
30.   Flaherty, L.E., P.Y. Liu, M.S. Mitchell, W.S. Fletcher, Walker, MJ, J.W. Goodwin, R.L. Stephens, and V.K. Sondak.
  The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). American Journal of Clinical Oncology 19: 108-113, 1996.
31.   Fraser, C.L. and R.A. Swanson.
  Female sex hormones inhibit volume regulation in rat brain astrocyte culture. American Journal of Physiology 267: C909-C9141994.
32.   Gattis, W.A. and D.B. May.
  Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. [Review] [20 refs]. Annals of Pharmacotherapy 30: 520-526, 1996.
33.   Gradishar, W.J. and V.C. Jordan.
  Clinical potential of new antiestrogens. [Review] [138 refs]. Journal of Clinical Oncology 15: 840-852, 1997.
34.   Greenberg, H.S.
  Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin - corroborating clinical response in vitro: Case report:Comment. Neurosurgery 38: 5911996.
35.   Hahnel, R. and M. Gschwendt.
  The interaction between protein kinase C (PKC) and estrogens (Review). International Journal of Oncology 7: 11-16, 1995.
36.   Haux, J.
  Digitoxin is a potential anticancer agent for several types of cancer. [Review] [50 refs]. Medical Hypotheses 53: 543-548, 1999.
37.   Huncharek, M. and J. Muscat.
  Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Research 18: 1303-1311, 1998.
38.   Ikemoto, H., E. Tani, T. Matsumoto, A. Nakano, and J. Furuyama.
  Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. Journal of Neurosurgery 83: 1008-1016, 1995.
39.   Iwasaki, K., S.A. Toms, G.H. Barnett, M.L. Estes, M.K. Gupta, and B.P. Barna.
  Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells. Cancer Immunology, Immunotherapy 40: 228-234, 1995.
40.   Kellen, J.A.
  Genomic effects of tamoxifen. [Review] [52 refs]. Anticancer Research 16: 3537-3541, 1996.
41.   Kuiper, G.G., B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nilsson, and J.A. Gustafsson.
  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870, 1997.
42.   Lee, Y.S. and R.D. Wurster.
  . Bepridil enhances in vitro antitumor activity of antiestrogens in human brain tumor cells. Cancer Letters 110: 243-248, 1996.
43.   Leslie, K.K., D. Keefe, S. Powell, and F. Naftolin.
  Estrogen receptors are identified in the glioblastoma cell line U138MG. Journal of the Society for Gynecologic Investigation 1: 238-244, 1994.
44.   Lesser, G.J.
  Chemotherapy of cerebral metastases from solid tumors. [Review] [73 refs]. Neurosurgery Clinics of North America 7: 527-536, 1996.
45.   Lifshits, A.L.
  [Special features in the clinical aspects of brain tumors in children]. [Russian]. Meditsinskaia Sestra 32: 19-21, 1973.
46.   Lippmann, M.E. and G. Bolan.
  . Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256: 592-593, 1975.
47.   Luo, W., T.R. Sharif, P.J. Houghton, and M. Sharif.
  CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth & Differentiation 8: 1225-1240, 1997.
48.   Mastronardi, L., J.O. Farah, F. Puzzilli, and A. Ruggeri.
  Tamoxifen modulation of carboplatin cytotoxicity in a human U-138 glioma cell line. Clinical Neurology & Neurosurgery 100: 89-93, 1998.
49.   Mastronardi, L., F. Puzzilli, W.T. Couldwell, J.O. Farah, and P. Lunardi .
  Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. Journal of Neuro-Oncology 38: 59-68, 1998.
50.   Mastronardi, L., F. Puzzilli, and A. Guiducci.
  Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy [letter; comment]. Neurosurgery 43: 14961998.
51.   Mastronardi, L., F. Puzzilli, and A. Ruggeri.
  Tamoxifen as a potential treatment of glioma. [Review] [65 refs]. Anti-Cancer Drugs 9: 581-586, 1998.
52.   Musella, A.
  Virtual Trials for Brain Tumors. Ongoing Study. http://www.virtualtrials.com 2000
53.   Nieder, C., K. Walter, U. Nestle, and K. Schnabel.
  Ten years disease-free survival after solitary brain metastasis from breast cancer. Journal of Cancer Research & Clinical Oncology 122: 570-572, 1996.
54.   Peto, R., J. Boreham, M. Clarke, C. Davies, and V. Beral.
  UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 18222000.
55.   Piepmeier, J.M.
  . Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: Corroborating clinical response in vitro:Case report- Comment. Neurosurgery 38: 590-591, 2000.
56.   Pollack, I.F. and S. Kawecki.
  The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatric Neurosurgery 22: 281-288, 1995.
57.   Pollack, I.F., S. Kawecki, and J.S. Lazo.
  Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. Journal of Neurosurgery 84: 1024-1032, 1996.
58.   Pollack, I.F., R.C. DaRosso, P.L. Robertson, R.L. Jakacki, J.R.J. Mirro, J. Blatt, S. Nicholson, R.J. Packer, J.C. Allen , A. Cisneros, and V.C. Jordan.
  A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clinical Cancer Research 3: 1109-1115, 1997.
59.   Pollack, I.F. and S. Kawecki.
  The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. Journal of Neuro-Oncology 31: 255-266, 1997.
60.   Pollack, I.F., M. Bredel, and M. Erff.
  Application of signal transduction inhibition as a therapeutic startegy for central nervous system tumors. Pediatric Neurosurgery 29: 228-244, 1998.
61.   Powles, T., R. Eeles, S. Ashley, D. Easton, J. Chang, M. Dowsett, A. Tidy, J. Viggers, and J. Davey.
  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial [see comments]. Lancet 352: 98-101, 1998.
62.   Preul, M.C., Z. Caramanos, J.G. Villemure, G. Shenouda, R. LeBlanc, A. Langleben, and D.L. Arnold.
  Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46: 306-318, 2000.
63.   Pritchard, K.I.
  Is tamoxifen effective in prevention of breast cancer? [comment] [see comments]. Lancet 352: 80-81, 1998.
64.   Rabinowicz, A.L., D.R. Hinton, P. Dyck, and W.T. Couldwell.
  High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 36: 513-515, 1995.
65.   Richard, M.A., J.J. Grob, H. Zarrour, N. Basseres, J.P. Bizzari, B. Gerard, and J.J. Bonerandi.
  Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma Research 8: 170-174, 1998.
66.   Rostagno, P., J.L. Moll, I. Birtwisle-Peyrottes, F. Ettore, J.L. Lagrange, J. Gioanni, and C. Caldani.
  Effects of tamoxifen on potential doubling time of human breast cancer cell line determined by image cytometry of double fluorescent BrdU and DNA labeling. Anticancer Research 14: 2025-2032, 1994.
67.   Sasco, A.J., R. Ah-Song, S. Saez, and F. Kuttenn.
  . [Medical adverse effects of chemoprevention: the example of tamoxifen]. [Review] [116 refs] [French]. Bulletin du Cancer 82 Suppl 3: 186s-206s, 1995.
68.   Sharif, M.
  Mitogenic signaling by substance P and bombesin-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines (review). International Journal of Oncology 12: 273-286, 1998.
69.   Sharif, T.R. and M. Sharif.
  A novel approach for examining the anti-proliferative effect of protein kinase C inhibitors against human astrocytoma cells. International Journal of Oncology 13: 685-692, 1998.
70.   Sharif, T.R. and M. Sharif.
  A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells. International Journal of Oncology 14: 327-335, 1999.
71.   Shlebak, A.A. and D.B. Smith.
  Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemotherapy & Pharmacology 39: 462-466, 1997.
72.   Shy, H., L. Malaiyandi, and P.S. Timiras.
  Protective action of 17 beta-estradiol and tamoxifen on glutamate toxicity in glial cells. International Journal of Developmental Neuroscience 18: 289-297, 2000.
73.   Simonetti, R.G., A. Liberati, C. Angiolini, and L. Pagliaro.
  Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. [Review] [54 refs]. Annals of Oncology 8: 117-136, 1997.
74.   Soroceanu, L., T.J.J. Manning, and H. Sontheimer.
  Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. Journal of Neuroscience 19: 5942-5954, 1999.
75.   Stearns, V. and E.P. Gelmann.
  Does tamoxifen cause cancer in humans? [see comments]. [Review] [143 refs]. Journal of Clinical Oncology 16: 779-792, 1998.
76.   Toms, S.A., A. Hercbergs, J. Liu, S. Kondo, T. Haqqi, G. Casey, K. Iwasaki, G.H. Barnett, and B.P. Barna.
  Antagonist effect of insulin-like growth factor I on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-xL. Journal of Neurosurgery 88: 884-889, 1998.
77.   Uhm, J.H., N.P. Dooley, J.G. Villemure, and V.W. Yong.
  Mechanisms of glioma invasion: role of matrix-metalloproteinases. [Review] [143 refs]. Canadian Journal of Neurological Sciences 24: 3-15, 1997.
78.   vanRijswijk RE, O.R. van, and A. Twijnstra.
  A case of brain metastases from male breast cancer responding to tamoxifen [letter]. European Journal of Cancer 33: 2282-2283, 1997.
79.   Veronesi, U., P. Maisonneuve, A. Costa, V. Sacchini, C. Maltoni, C. Robertson, N. Rotmensz, and P. Boyle.
  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study [see comments]. Lancet 352: 93-97, 1998.
80.   Weller, M., M. Trepel, C. Grimmel, M. Schabet, D. Bremen, S. Krajewski, Reed, and JC.
  Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. Neurological Research 19: 459-470, 1997.
81.   Williams, C.J.
  Tamoxifen in relapsed ovarian cancer: A systematic review. International Journal of Gynecological Cancer 8: 89-94, 1998.
82.   Wogan, G.N.
  Review of the toxicology of tamoxifen. [Review] [36 refs]. Seminars in Oncology 24: S1-S11997.
83.   Wolf, D.M. and S.A. Fuqua.
  Mechanisms of action of antiestrogens. [Review] [175 refs]. Cancer Treatment Reviews 21: 247-271, 1995.
84.   Zeltzer, P.M., B. Moilanen, J.S. Yu, and K.L. Black.
  Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application. [Review] [84 refs]. Childs Nervous System 15: 514-528, 1999.
85.   Zhang, W., D.R. Hinton, A.A. Surnock, and W.T. Couldwell.
  Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Neurosurgery 38: 587-590, 1996.
86.   Zhang, W., R.E. Law, D.R. Hinton, and W.T. Couldwell.
  Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Letters 120: 31-38, 1997.

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557

Website Design By
World Wide Websites